Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | ABL2 | P42684 | 1/20 | 0.49 |
| ▸ | PYGL | P06737 | 8/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | NHERF1 | O14745 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733565 | 0.94 | ADH1A (0.48) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL12251618 | 0.94 | ADH1A (0.48) | ADH1AKITFLT1FLT4KDR | |
| Seco-Cbi-Indole SCHEMBL29468891 | 0.93 | ADH1A (0.51) | ADH1AKITFLT1FLT4KDR | |
| Seco-Cbi-Indole SCHEMBL12596993 | 0.93 | ADH1A (0.51) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL6522948 | 0.93 | ADH1A (0.56) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL5496302 | 0.93 | ADH1A (0.56) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL14301817 | 0.92 | PYGL (0.41) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL13309194 | 0.92 | PYGL (0.41) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL436461 | 0.91 | ADH1A (0.49) | ADH1AKITFLT1FLT4KDR | |
| SCHEMBL12508919 | 0.91 | ADH1A (0.49) | ADH1AKITFLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250269050-A1 | CYCLIC DICHALCOGENIDE ADC LINKER UNITS AND USES THEREOF | THORN SESHOLD OLIVER (DE) | 2025-08-28 | — | — | US | disclosed |
| WO-2025078841-A2 | ANTIBODIES, CONJUGATES, AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-20210369705-A1 | COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS | MERCK PATENT GMBH (DE) | 2021-12-02 | — | — | US | disclosed |
| US-7906545-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110008373-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7655660-B2 | Antitumor antibiotic; water solubility, stability; N-[2-{(1-chloromethyl)-1,2-dihydro-5-[(4-methylpiperazino)carbonyloxy]-3H-benz(e)indol-3-yl}carbonyl]-1H-indol-5-yl]-5-[(3-methyldithio-1-oxopropyl)-amino]-1H-indole-2-carboxamide | IMMUNOGEN INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655661-B2 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-20090281158-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20080260685-A1 | PRODRUGS OF CC-1065 ANALOGS | IMMUNOGEN INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20070135346-A1 | Prodrugs of CC-1065 analogs | IMMUNOGEN INC. | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260685-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, DNPEP, CLSPN | ADH1A 3937/4885KIT 3488/4885FLT1 2140/4885 |
| US-20090281158-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, DNPEP, PRCP | ADH1A 3929/4885KIT 3409/4885FLT1 2341/4885 |
| US-20210369705-A1 | COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS | ATR, TOP2A, TOP1 | ADH1A 3241/4885KIT 2021/4885FLT1 1312/4885 |
| US-20110008373-A1 | PRODRUGS OF CC-1065 ANALOGS | CASP5, DNPEP, PRCP | ADH1A 3929/4885KIT 3409/4885FLT1 2341/4885 |
| US-20250269050-A1 | CYCLIC DICHALCOGENIDE ADC LINKER UNITS AND USES THEREOF | CCL2, UACA, CAD | ADH1A 3820/4885KIT 3435/4885FLT1 2147/4885 |
| US-20070135346-A1 | Prodrugs of CC-1065 analogs | CASP5, DNPEP, PRCP | ADH1A 3929/4885KIT 3409/4885FLT1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.